Search research articles
Contact Us
Filters
Showing results (61-70 of 70) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 70 results.
Therapeutic Advances in Gastroenterology
|
September 2, 2025
The CROCO (CROhn's Disease COhort Study) - study design and protocol
Joana Revés, Anthony Buisson, Johan Burisch, et al.
Alimentary Pharmacology & Therapeutics
|
July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
Matthew Bohm, Ronghui Xu, Yiran Zhang, et al.
United European Gastroenterology Journal
|
August 19, 2025
Patient and First-Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease-A Multinational Survey
Ana Catarina Bravo, Sara Godt Christensen, Mette Julsgaard, et al.
Gastroenterology
|
November 15, 2021
Integrative Analysis of the Inflammatory Bowel Disease Serum Metabolome Improves Our Understanding of Genetic Etiology and Points to Novel Putative Therapeutic Targets
Antonio F Di'Narzo, Sander M Houten, Roman Kosoy, et al.
Cell
|
September 3, 2019
Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy
Jerome C Martin, Christie Chang, Gilles Boschetti, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis
David M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
Dana Lukin, David Faleck, Ronghui Xu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 17, 2020
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
Parambir S Dulai, Siddharth Singh, Niels Vande Casteele, et al.
Nature Medicine
|
February 22, 2022
Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity
Mathieu Uzzan, Jerome C Martin, Luka Mesin, et al.
Elife
|
January 23, 2019
Gut microbiota density influences host physiology and is shaped by host and microbial factors
Eduardo J Contijoch, Graham J Britton, Chao Yang, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 70) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 70 results.
Therapeutic Advances in Gastroenterology
|
September 2, 2025
The CROCO (CROhn's Disease COhort Study) - study design and protocol
Joana Revés, Anthony Buisson, Johan Burisch, et al.
Alimentary Pharmacology & Therapeutics
|
July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
Matthew Bohm, Ronghui Xu, Yiran Zhang, et al.
United European Gastroenterology Journal
|
August 19, 2025
Patient and First-Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease-A Multinational Survey
Ana Catarina Bravo, Sara Godt Christensen, Mette Julsgaard, et al.
Gastroenterology
|
November 15, 2021
Integrative Analysis of the Inflammatory Bowel Disease Serum Metabolome Improves Our Understanding of Genetic Etiology and Points to Novel Putative Therapeutic Targets
Antonio F Di'Narzo, Sander M Houten, Roman Kosoy, et al.
Cell
|
September 3, 2019
Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy
Jerome C Martin, Christie Chang, Gilles Boschetti, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis
David M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
Dana Lukin, David Faleck, Ronghui Xu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 17, 2020
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
Parambir S Dulai, Siddharth Singh, Niels Vande Casteele, et al.
Nature Medicine
|
February 22, 2022
Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity
Mathieu Uzzan, Jerome C Martin, Luka Mesin, et al.
Elife
|
January 23, 2019
Gut microbiota density influences host physiology and is shaped by host and microbial factors
Eduardo J Contijoch, Graham J Britton, Chao Yang, et al.
Page
of 7